Trial Profile
A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients with Staphylococcus aureus Bloodstream Infections (Bacteremia) Including Endocarditis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Exebacase (Primary)
- Indications Bacteraemia; Endocarditis; Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors ContraFect
- 04 Oct 2021 According to a ContraFect media release, data from this trial presented at IDWeek 2021.
- 04 Oct 2021 Results presented in the ContraFect Media Release.
- 29 Sep 2021 According to a ContraFect media release, data from this trial will be presented at IDWeek 2021.